Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Study

Pfizer presented detailed results from an ongoing Phase 2 study investigating tilrekimig in adults with moderate-to-severe atopic dermatitis. The study met its primary endpoint, demonstrating a statistically significant increase in skin clearance.